Literature DB >> 20670818

Evolution of conventional therapy in atopic dermatitis.

Andreas Wollenberg1, Christina Schnopp.   

Abstract

Conventional therapy for atopic dermatitis has evolved along with better understanding of underlying impaired barrier function, role of microorganisms, and immune abnormalities. Emollients, along with antimicrobial and topical anti-inflammatory therapies, remain the cornerstone of conventional therapy. Recent therapeutic advances include use of nonsteroidal therapy for epidermal barrier repair, along with proactive therapy with topical corticosteroids and calcineurin inhibitors. Minimal anti-inflammatory treatment of the underlying residual disease is the immunobiologic rationale for proactive therapy. Further progress in understanding this increasingly common disease will hopefully lead to more targeted therapies. Copyright 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20670818     DOI: 10.1016/j.iac.2010.06.005

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  8 in total

1.  Aspartame Attenuates 2, 4-Dinitrofluorobenzene-Induced Atopic Dermatitis-Like Clinical Symptoms in NC/Nga Mice.

Authors:  Gun-Dong Kim; Yong Seek Park; Hyun-Jong Ahn; Jeong-Je Cho; Cheung-Seog Park
Journal:  J Invest Dermatol       Date:  2015-06-22       Impact factor: 8.551

Review 2.  [Topical therapy for atopic eczema].

Authors:  M Knop; A Gürtler; A Heratizadeh; N Aszodi; Th Werfel; A Wollenberg
Journal:  Hautarzt       Date:  2018-03       Impact factor: 0.751

3.  Long term treatment concepts and proactive therapy for atopic eczema.

Authors:  Andreas Wollenberg; Laura Maximiliane Ehmann
Journal:  Ann Dermatol       Date:  2012-07-25       Impact factor: 1.444

4.  The stable cyclic adenosine monophosphate analogue, dibutyryl cyclo-adenosine monophosphate (bucladesine), is active in a model of acute skin inflammation.

Authors:  Chris Rundfeldt; Hartwig Steckel; Torben Sörensen; Piotr Wlaź
Journal:  Arch Dermatol Res       Date:  2012-05       Impact factor: 3.017

Review 5.  Personalized medicine-concepts, technologies, and applications in inflammatory skin diseases.

Authors:  Thomas Litman
Journal:  APMIS       Date:  2019-05       Impact factor: 3.205

Review 6.  Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence.

Authors:  Andreas Wollenberg; Simon Francis Thomsen; Jean-Philippe Lacour; Xavier Jaumont; Slawomir Lazarewicz
Journal:  World Allergy Organ J       Date:  2021-03-19       Impact factor: 4.084

Review 7.  Atopic Dermatitis as a Multifactorial Skin Disorder. Can the Analysis of Pathophysiological Targets Represent the Winning Therapeutic Strategy?

Authors:  Irene Magnifico; Giulio Petronio Petronio; Noemi Venditti; Marco Alfio Cutuli; Laura Pietrangelo; Franca Vergalito; Katia Mangano; Davide Zella; Roberto Di Marco
Journal:  Pharmaceuticals (Basel)       Date:  2020-11-22

8.  Real-World Evidence of an Emollient Device for Atopic and Contact Dermatitis in Pediatric to Adult Patients - Data from a Post-Marketing Surveillance.

Authors:  Adelaide Ann Hebert
Journal:  Clin Cosmet Investig Dermatol       Date:  2022-09-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.